CoChat
Sign Up
Cited by 18Estrogen and related hormone effectsAdvanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer

Bruning, PF, Bonfrèr, JGM, Engelsman, E, Hamersma-v.d. Linden, E, de Jong-Bakker, M, Nooyen, W·1984·Breast Cancer Research and Treatment
DOI 10.1007/bf01806041
Open this paper in CoChat — free account

Abstract

In a phase II clinical trial, 38 postmenopausal women with advanced breast cancer were treated with aminoglutethimide and replacement hydrocortisone. All women had previously received up to 4 modalities of endocrine therapy. Seventeen patients had also been treated with cytostatic drugs. Twenty-five percent of the 29 evaluable patients experienced objective tumor regression, lasting from 11 to more than 18 months. In 29% the disease was stabilized for 3 to more than 15 months. Toxicity was significant, necessitating drug withdrawal in 3 patients. One patient died within 3 weeks of therapy from multiple perforated gastric ulcers. Two patients developed herpes zoster within 4 weeks of treatment. Many side effects were minor and transient. However, treatment resulted in overt primary hypothyroidism in 25% of the evaluable patients and in a strongly increased need of acenocoumarin in all 3 patients on anticoagulant therapy.

Integrity signals

Registry

Crossref · 10.1007/bf01806041

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Of 32 women under aminoglutethimide + hydrocortisone for advanced breast cancer, 17 (53%) had hyperthyrotropinemia before treatment; in 15/17 patients, TSH increased further, with seven developing overt hypothyroidism.

    “Of 32 women under aminoglutethimide + hydrocortisone for ABC, 17 (53%) had hyperthyrotropinemia before treatment. In 15/17 patients, TSH increased further, with seven developing OH (68).”

    From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [68]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Bruning, P., Bonfrèr, J., Engelsman, E., Hamersma-v.d. Linden, E., de Jong-Bakker, M., & Nooyen, W.
Affiliations
The Netherlands Cancer Institute (NL)
Venue
Breast Cancer Research and Treatment
Publisher
Springer Science and Business Media LLC
Published
1984-12
Volume
4
Issue
4
Pages
289-295
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
DOI
10.1007/bf01806041
OpenAlex
W2013206957
Cited by
18
References
26
Citations by year
2022: 1 · 2020: 1 · 2019: 1 · 2013: 1
FWCI
1.50
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
aminoglutethimide, advanced breast cancer, postmenopausal women, hydrocortisone replacement, endocrine therapy, tumor regression, drug toxicity, gastric ulcer, herpes zoster, primary hypothyroidism, acenocoumarol, anticoagulation
MeSH terms
Aminoglutethimide, Breast Neoplasms, Female, Humans, Hydrocortisone, Menopause, Middle Aged, Thyrotropin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review